{
    "2021-04-25": [
        [
            {
                "time": "",
                "original_text": "国内医药界的“卖水人”正处十年黄金期，未来仍有8-12倍收入提升空间！",
                "features": {
                    "keywords": [
                        "医药界",
                        "卖水人",
                        "十年黄金期",
                        "收入提升空间"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "凯莱英（002821）2021年一季报点评：业绩基本符合我们预期，汇率及股权激励费用影响表观增速！【东吴医药朱国广团队】",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "2021年一季报",
                        "业绩预期",
                        "汇率",
                        "股权激励费用",
                        "表观增速"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}